DMD has made its digital content distribution enterprise in the last two years. Along with that, it has developed a global cinema TVOD (Transactional Video On Demand product). The company has built a long-term distribution partnership with OTT companies, telephone/IPTV and major cable that lead the wealthiest portion of the Pay TV market, providing service to 17 million two-way homes in 19 nations in Latin America. DMD's revenue has increased by 93% YoY 2017-2018, which will help the company in reaching EBITDA breakeven in Q3 of 2019. DMD has established relationships with distributors and leading sales agents in Europe and the USA. With the proceeds, the company will acquire bigger commercial films, increase its global footprint by launching the company in Asia, Africa, and Europe, and supplement its current output with classic titles.
/* OVERVIEW */ ?>
DMD Rating Review
Pitch rating powered by CROWDRATING™
Rated on 08/04/2020
Log in to view target
£2,925,000
pre-money valuation
5
investors
£29,000
pledge per investor
08756268
company number
Active
company status
31/10/2013
incorporated 11 years
Previous Funding rounds
23 Apr 24 | Envestors | £145,000 / 15% | 69.67% |
News
Glucocorticoid use can help breathing ability in DMD adults: Study - Muscular Dystrophy News
23/04/2024 Muscular Dystrophy News
Ohio first in US to screen newborns for DMD. Here's what to know - The Columbus Dispatch
24/04/2024 The Columbus Dispatch
Standard Criteria for Loss of Ambulation Needed in DMD - AJMC.com Managed Markets Network
20/04/2024 AJMC.com Managed Markets Network
Novel ASO screening study paves the way for duchenne muscular dystrophy (DMD) therapy advancements - News-Medical.Net
20/02/2024 News-Medical.Net
DMD candidate SGT-003 receives Rare Pediatric Disease Designation - Contemporary Pediatrics
02/04/2024 Contemporary Pediatrics
Rethinking capital allocation key to sustainable growth - Fidelity Bank DMD - The Business & Financial Times
24/04/2024 The Business & Financial Times
Italfarmaco wins FDA's blessing for nonsteroidal DMD therapy - FiercePharma
22/03/2024 FiercePharma
Exondys 51 extends survival in DMD, long-term study shows - Muscular Dystrophy News
09/04/2024 Muscular Dystrophy News
Glucocorticoids Preserve Late-Stage Functional Abilities in DMD After Loss of Ambulation, Study Finds - AJMC.com Managed Markets Network
12/04/2024 AJMC.com Managed Markets Network
Rollout expected by fall in US for approved DMD therapy Duvyzat - Muscular Dystrophy News
02/04/2024 Muscular Dystrophy News
What the ratings mean
RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.